What is cGP and how cGPmax works

What is cGP?
cGP (Cyclic Glycine-Proline) is a key molecule in your body whose job is to regulate the function of a life-supporting hormone called IGF-1 (Insulin-like Growth Factor 1).
IGF-1 is responsible for making capillaries - the smallest blood vessels in our body. They transport oxygen and nutrients to cells and remove waste from our brain and main organs.
Our IGF-1 function reduces as we age, or can occur prematurely as a result of poor lifestyle and stress.
Taking a daily dose of cGPMAX™ increases the cGP levels in your body, in turn powering the IGF-1 to produce more capillaries.
If you would like to know more about the science of cGP and IGF-1 and how it positively impacts health outcomes, we have an extensive list of scientific papers and research available. Learn More...

In other words…
Let’s use an analogy to better explain the role of cGP and IGF-1…
Imagine the blood vessels in your body are roads in a city, and the IGF-1 is responsible for road maintenance.
As the city grows over time and the roads are under constant use, the original roads will not last, they will deteriorate until the cars can no longer use them.
When we are young the roads are being constantly maintained. However, as we age our IGF -1 levels drop so IGF-1 just doesn’t do any road maintenance or doesn’t build new roads.

In addition to ageing, when a person is young and a natural disaster strikes the body, (for example caused by injury or stress), there is an increased use of the body’s roading system. This causes a greater need for road maintenance.
This is where the cGP becomes the hero. The cGP acts like a superfood and fuels the IGF-1 and the more cGP you put into your body, the faster and harder the IGF-1 works to repair body’s roading system, facilitating the delivery of oxygen and nutrients to the cells in the brain and body and enabling the removal of waste.

cGPMAX™ Brain Health
There is no known way of medically controlling the IGF-1 function in our body. Taking a cGPMAX Brain Health is the only known way to regulate the IGF-1 to keep it functioning at its optimum level for good health.
cGPMAX™ Brain Health has been scientifically researched and formulated to increase the supply of nutrients to the brain, supporting brain health and function as we age.
It is 100% naturally sourced and you cannot have too much as any excess is passed out with your urine.
Take your brain health into your own hands and start the cGPMAX™ journey with a Brain Health Start Pack.
Age Well with cGP
Our Chief Scientist Dr Jian Guan has written over 80 scientific papers about the role of cGP and how it effects people suffering from various neurodegenerative diseases.
We encourage you to have a look our scientific papers to understand how cGP impacts the effects of these diseases and can work towards easing the effects of the disease to give people a better outcome for their future.
- 2021 Singh-Mallah G, Ardalan M, Singh K, Kang D, McMahon C, Mallard C and Guan J. Administration of cyclic glycine-proline during infancy improves adult spatial memory, astrocyte plasticity, vascularization and GluR-1 expression in rats. Nutritional Neuroscience. August 2021
- 2021 Kang D, Waldvogel H, Fan D, Wang A, Faull R, Curtis M, Shorten P and Guan J. The autocrine regulation in human brain of Alzheimer’s diseases. Accepted with revision in Psychoneuroendocrinology
- 2020 Fan D, Pitcher T, Dalrymple-Alford J, MacAskill M, Anderson T and Guan J. Plasma cGP/IGF-1 molar ratio is associated with cognitive status of Parkinson disease. Alzheimer’s Dement. 2020;1–10.
- 2019 Li FX, Liu K, Gray C, Harris P, Reynolds C, Vickers M and Guan J. Cyclic glycine-proline normalizes systolic blood pressure in high-fat diet-induced obese male rats. Nutrition, Metabolism & Cardiovascular Diseases. 30: 339-346
- 2019 Li FX, Liu K, Wang A, Harris P, Vickers M and Guan J. Cyclic Glycine-Proline Administration Normalizes High-Fat Diet-Induced Synaptic Expressions in Obese Rats. Neuropeptides 76, 101935, 10.1016/j.npep.2019.05.006
- 2019 Fan D, Krishnamurthi R, Harris P, Barber PA, Guan J. Plasma cyclic glycine proline/IGF-1 ratio predicts clinical outcome and recovery in stroke patients. Annals of Clinical Translational Neurology 2019;0
- 2018 Fan D, Alamri Y, Liu K, MacAskill M, Harris P, Brimble M, et al. Supplementation of Blackcurrant Anthocyanins Increased Cyclic Glycine-Proline in the Cerebrospinal Fluid of Parkinson Patients: Potential Treatment to Improve Insulin-Like Growth Factor-1 Function. Nutrients 2018;10:714. doi:10.3390/nu10060714.
- 2018 Alamri Y, The use of dietary supplements and perceived quality of life in patients with Parkinson's disease. J Clin Neuroscience 56: 137-136
- 2018 GUAN J, SINGH-MALLAH G, LIU K, SHORTEN P, THOMPSON J, MITCHELL E, TAYLOR R, HARRIS P, BRIMBLE M, THORSTENSEN E AND MURPHY R. The role for autocrine regulation of IGF-1 in pregnancy related obesity, a potential biomarker for weight changes. Journal of Biological Regulators and Homeostatic agents 32(3): 11-25
- 2017 SINGH-MALLAH G, MCMAHON CD, GUAN J and SINGH K Cyclic-glycine-proline promotes post-lactational involution in mammary glands of rats through inhibiting IGF 1 function. Journal of Cellular Physiology 232 (12) 3369-3383doi: 10.1002/jcp.25782
- 2016 SINGH-MALLAH G, SINGH K, MCMAHON CD, HARRIS P, BRIMBLE MA and GUAN J, Maternal-infantile transfer following oral administration of cyclic-glycine-proline in lactating rats and its effect on improving memory in the offspring Endocrinology 157(8):3130-9
- 2017 YANG P, WALDVOGEL H, Scott E, FAULL R, DRAGUNOW M, TURNER C, AND GUAN J. Endothelial degeneration of Parkinson disease is related to alpha-synuclein aggregation. Journal of Alzheimer’s Disease & Parkinsonism 7: 370. doi: 10.4172/2161-0460.1000370
- 2017 YANG P, WALDVOGEL H, FAULL R, DRAGUNOW M, TURNER C, AND GUAN J. Vascular remodelling is impaired in Parkinson’s diseases, Journal of Alzheimer’s Disease & Parkinsonism 7: 313. doi: 10.4172/2161-0460.1000313
- 2015 Yang P, Pavlovic D, Richard Faull, Mike Dragunow Beth Synek, Clinton Turner Henry Waldvogel and Guan J, String vessel formation is increased in the brain of Parkinson disease. J of Parkinson Diseases. 5 (2015) 821–8362015
- 2015 GUAN J, HARRIS P, BRIMBLE M, LEI Y, LU J, YANG Y AND J GUNN A, The role for IGF-1 derived small neuropeptides as a therapeutic target for neurological disorders. Expert Opinion on Therapeutic Targets. Invited review 2015 Feb 5:1-9
- 2015 PHILLIPS GMA, SHORTEN PR, WAKE GC AND GUAN J, Dynamical modelling of the effect of insulin-like growth factor -1 on human cell growth. Mathematical Bioscience Journal 2015 Jan; 259:43-54.
- 2014 GUAN J, GLUCKMAN PD, YANG PZ, KRISSANSEN G, SUN K, ZHOU Y, WEN JY, SHORTEN P, WAKE G, MCMAHON CD, THOMAS MF, PHILIP G, CHEN W, S MOON, A REN AND LIU DX, Cyclic glycine-proline regulates IGF-1 homeostasis by altering the binding of IGFBP-3 to IGF-1 Scientific Report, 4, 4388
- 2014 MATHAI S, GUNN AJ, BRIMBLE MA, HARRIS PW AND GUAN J. Neuroprotection with Glycin-2methyl-Proline-Glutamate (G-2mPE) after hypoxic-ischemic brain injury in adult rats. Journal of Experimental Stroke Translational Medicine 6: 1-112013
- 2013 GUAN J, MATAI S, LIANG HP AND GUNN JA Insulin-like growth factor-1 and its derivatives: Potential pharmaceutical application for treating neurological conditions. Recent Patents on CNS drug discovery 2013 8(2) 142-168
- 2013 Guan J, Pavlovic D, Darkie N, Waldvigel H, Green C and Nicholson L. Vascular degeneration of Parkinson Disease. Brain Pathology 23(2) 154-164 (impact factor 4.7 doi: 10.1111/j.1750-3639.2012628)
- 2012 MATHAI S, GUNN AJ, BACKHAUS A AND GUAN J Window of opportunity for neuroprotection with an antioxidant, Allene Oxide Synthase, after hypoxia-ischemia in adult male rats, Journal of Neuroscience and Therapeutics 18(11):887-94
- 2012 ZHANG R, KADAR T, SIRIMANNE E, MACGIBBON A AND GUAN J Age-related memory decline in rats is associated with vascular and microglial degeneration, Behavioural Brain Research 1;235(2):210-7
- 2010 GUAN J, ZHANG R, L DALE GANDAR AND VICKERS M. NNZ-2591, A novel diketopiperazine, prevented scopolamine-induced acute memory impairment in the adult rat. Behavioural Brain Research 210, 221-228.
- 2009 GUAN J AND GLUCKMAN P. Endogenous small neuropeptides and their analogues: a novel strategy for the development of pharmaceuticals for neurological conditions, invited review by British Journal of Pharmacology 157, 881-891
- 2009 SHAPIRA S, MATHAI S, ZHANG R AND GUAN J Delayed peripheral administration of the N-terminal tripeptide of IGF-1 (GPE) reduces brain damage following microsphere induced embolic damage in young adult and aged rats. Neuroscience Letter 454 (1) 53-57
- 2009 KRISHNAMURTHI, R V M., KIM A H., MATHAI S. RONG ZHANG AND GUAN J. Delayed treatment with a novel diketopiperazine improves motor function after 6-OHDA lesion in rats. British Journal of Pharmacology 156, 662-672.
- 2008 JACOBSON L, ZHANG R, ELLIFFE D, CHEN C, MATHAI S, MCCARTHY D, WALDVOGE H AND GUAN J. Co-relation of cellular/vascular changes and spatial memory during aging in rats Experimental Gerontology 43, 928-938
- 2007 GUAN J, MATHAI S, HARRIS P, BRIMBLE M, WEN JY ZHANG R and GLUCKMAN P Peripheral administration of a novel diketopiperazine, NNZ 2591 prevents brain injury and improves somatosensory-motor function following hypoxia-ischemia in adult rats. Neuropharmacolocy 53: 749-762
- 2007 SVEDIN P, GUAN J*(co-responding author), MATHAI S, ZHANG R, WANG XY, HAGBERG H AND MALLARD C Delayed peripheral administration of a GPE analogue induces astrogliosis and angiogenesis and reduces inflammation and brain injury following hypoxia-ischemia in the neonatal rat. Developmental neuroscience 29: 393-402
- 2005 BAKER A M, BATCHELOR D C, THOMAS G B, CLARK R G, RAFIEE M, LIN H AND GUAN J Central penetration and the stability of N-terminal tripeptide of insulin-like growth factor-I, glycine-proline-glutamate in adult rat. Neuropeptides 39(2) 81-87
- 2004 GUAN J, THOMAS G B, LIN H, MATAI S, BACHELOR D C, GEORGE S, FERNANDEZ J AND GLUCKMAN PD Neuroprotective effects of the N-terminal tripeptide of insulin-like growth factor –1, glycine-proline-glutamate (GPE) following intravenous infusion in hypoxic-ischemic adult rats. Neuropharmacology Vol 47 (6): 892-903
- 2004 KRISHNAMURTHI R, STOTT S, MAINGAY M, FAULL RLM, MCCARTHY D, GLUCKMAN PD AND GUAN J. N-terminal tripeptide of insulin-like growth factor –1 (GPE) improves functional deficits after 6-OHDA lesion in rats. NeuroReport 15(10); 1601-1604
- 2003 GUAN J, BENNET L PD GLUCKMAN AND GUNN AJ, Insulin-like growth factor-1 and the ischemic brain. Progress in Neurology 70 (6), 443-462
- 2000 GUAN J., KRISHNAMURTHI, R., WALDVOGEL, H.J., FAULL, R.L.M., CLARK, R. AND GLUCKMAN, P. N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats. Brain Research 859 (2) 286-292,
- 1999, GUAN J, WALDVOGEL H, FAULL R, GLUCKMAN P AND WILLIAMS C The effects of the N-terminal tripeptide of insulin-like growth factor-1, glycine-proline-glutamate in different regions following hypoxic-ischemic brain injury in adult rats. Neuroscience 89: 649-659